...
首页> 外文期刊>Joint, bone, spine : >Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients
【24h】

Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients

机译:风湿性疾病的孕妇在妊娠晚期接受Certolizumab治疗:脐带血中药物含量低,但可能会感染孕妇。一例13例

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Due to reduction of immune-suppressive drugs, patients with rheumatic diseases can experience an increase in disease activity during pregnancy. In such cases, TNF-inhibitors may be prescribed. However, monoclonal antibodies with the Fc moiety are actively transported across the placenta, resulting in therapeutic drug levels in the newborn. As certolizumab (CZP) lacks the Fc moiety, it may bear a lower risk for the child.
机译:目的:由于减少了免疫抑制药物,风湿性疾病患者在怀孕期间疾病活动可能会增加。在这种情况下,可开具TNF抑制剂。但是,具有Fc部分的单克隆抗体会通过胎盘主动转运,从而导致新生儿的治疗药物水平升高。由于塞妥珠单抗(CZP)缺少Fc部分,因此对儿童的风险可能较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号